UC San Diego Moores Cancer Center
San Diego's NCI comprehensive cancer centre, where the anti-GD2 antibody dinutuximab and the ROR1 antibody behind zilovertamab were developed.
NCI-designated since 1978 and comprehensive since 2001, Moores sits at the heart of the La Jolla biomedical cluster with the Salk Institute, Sanford Burnham Prebys and Scripps. Alice Yu led the Children's Oncology Group trial that established the anti-GD2 antibody dinutuximab in high-risk neuroblastoma. Thomas Kipps's CLL laboratory generated the humanised anti-ROR1 antibody (cirmtuzumab, UC-961) that became the targeting arm of the ADC zilovertamab vedotin. The centre also runs a large precision-oncology and phase 1 programme and hosts the Sanford Stem Cell Institute.
- Neuroblastoma immunotherapy (anti-GD2)
- CLL and ROR1
- Precision oncology
Pages like this
not linked directly; found by shared links- TrialCOG ANBL0032
Shares Alice L. Yu, Dinutuximab (ch14.18) / dinutuximab beta, GD2 (disialoganglioside), Children's Oncology Group (COG).
- InstitutionUniversity of Wisconsin Carbone Cancer Center
Shares Dinutuximab (ch14.18) / dinutuximab beta, GD2 (disialoganglioside), Children's Oncology Group (COG), Neuroblastoma (paediatric).
- PersonJulie R. Park
Shares Dinutuximab (ch14.18) / dinutuximab beta, GD2 (disialoganglioside), Children's Oncology Group (COG), Neuroblastoma (paediatric).
- TrialwaveLINE-003
Shares ROR1, Zilovertamab vedotin.
- PairingAnti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)
Shares Dinutuximab (ch14.18) / dinutuximab beta, GD2 (disialoganglioside), Neuroblastoma (paediatric).
- ProductNaxitamab
Shares GD2 (disialoganglioside), Monoclonal antibodies, Neuroblastoma (paediatric).
- InstitutionTexas Children's Cancer and Hematology Center
Shares GD2 (disialoganglioside), Children's Oncology Group (COG), Neuroblastoma (paediatric).
- PairingCaution: IL-2 added to anti-GD2 therapy
Shares Dinutuximab (ch14.18) / dinutuximab beta, Neuroblastoma (paediatric).